✦ LIBER ✦

Treatment strategy for HER2-positive breast cancer

✍ Scribed by Hirofumi Mukai

Publisher: Springer
Year: 2010
Tongue: English
Weight: 163 KB
Volume: 15
Category: Article
ISSN: 1341-9625
DOI: 10.1007/s10147-010-0107-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Progression and treatment of HER2-positi

Progression and treatment of HER2-positive breast cancer

✍ April Davoli; Barbara A. Hocevar; Thomas L. Brown 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 406 KB

Dual HER2-targeted approaches in HER2-po

Dual HER2-targeted approaches in HER2-positive breast cancer

✍ Eugene R. Ahn; Charles L. Vogel 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 520 KB

Optimal treatment strategies in postmeno

Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer

✍ Joseph Gligorov; Jean-Pierre Lotz 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 323 KB

Issues and controversies in the treatmen

Issues and controversies in the treatment of HER2 positive metastatic breast cancer

✍ Surabhi Amar; Alvaro Moreno-Aspitia; Edith A. Perez 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 153 KB

Cost-effectiveness analysis of trastuzum

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

✍ Louis P. Garrison Jr; Deborah Lubeck; Deepa Lalla; Virginia Paton; Amylou Dueck; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

## Abstract ## BACKGROUND. Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. A cost‐effectiveness analysis was performed to assess clinical and economic implications of adding t

Risk factors for brain relapse in HER2-p

Risk factors for brain relapse in HER2-positive metastatic breast cancer patients

✍ Renata Duchnowska; Rafał Dziadziuszko; Bogumiła Czartoryska-Arłukowicz; Barbara 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 219 KB